ITG distributes advanced wound care portfolios — antimicrobial matrices, bioengineered tissue allografts, amniotic membrane products, and cold plasma therapy — across Asia, Latin America, and Europe. Regulatory rigor, clinical support, and supply reliability built for markets that demand the highest standard of care.
sweetbio
terraplasma medical
By bridging cutting-edge U.S. manufacturers with forward-thinking healthcare providers abroad, we enable faster healing, improved patient care, and expanded access to regenerative solutions. Whether you're a clinic in Buenos Aires or a hospital in Bangkok — we deliver the technology, evidence, and support to treat wounds with confidence and precision.
Direct access to U.S.-manufactured amniotic membrane allografts — with the regulatory documentation, clinical support, and reliable supply your patients deserve. Built for hospitals, clinics, and surgeons treating chronic and complex wounds.
Build a region-leading regenerative wound care portfolio with vetted, clinically-validated U.S. biologics. ITG offers prime distribution agreements with regulatory support, marketing tools, and clinical evidence behind every territory.
ITG's primary portfolio is the Biolab range — antimicrobial matrices, bioengineered tissue allografts, amniotic membrane products, and cold plasma therapy. Multiple modalities. One distribution partner. Backed by peer-reviewed evidence and full clinical documentation in English and Thai.
Ionic and metallic silver at low, non-toxic levels — 99.99% microbial reduction on matrix. Conforms to wound-bed micro-crevices, maintains a moist healing environment. 7 sizes. HCPCS A2005.
Learn moreCollagen Derivative + Mānuka Honey + Hydroxyapatite — 2× faster wound closure in published peer-reviewed studies. 4–8 week wound closure, 99.99% bacteria reduction in 24 hours. HCPCS A2010.
Learn moreFour amniotic tissue allograft configurations — single, dual, hydrated, and triple-layer amnion-chorion-amnion. All sizes 1×1 through 10×10 cm. 5-year shelf life. FDA compliant.
Learn moreAcross published clinical studies and real-world outcomes data, the technologies we distribute consistently outperform conventional wound therapy — particularly in chronic ulcers where conventional care fails.
From Santiago to Sydney, Buenos Aires to Bangkok, Tokyo to Warsaw — ITG operates a vetted distribution network across markets where advanced regenerative wound care is most needed and most underserved.
From clinicians evaluating the Biolab range for chronic wound cases to in-country distributors building a full regenerative wound care portfolio, ITG is built for the partnerships that change patient lives.
Get in Touch